A new report finds that Medtronic or its subsidiaries were responsible for one-fifth of all medical device recalls last year, and raises questions about the company's commitment to avoid unfair…
A proposed rule by the FDA could allow medical device manufacturers to simply summarize malfunction reports quarterly, instead of providing full, detailed information.
The Supreme Court has been asked to weigh in on whether Medtronic is protected by preemption laws if if illegally promoted the Infuse bone growth system for off-label use.
The FDA is warning doctors to avoid regular use of bone growth products like Medtronics Infuse on children due to the risk of side effects to their still-growing bones.
Medtronic has agreed to pay $10 million to settle allegations that it paid off doctors to implant its devices in patients.
A $22 million Medtronic Infuse settlement has been reached that resolves 950 claims, but leaves hundreds more unresolved; a number likely to grow as more claims are filed.
Medtronic says it faces 1,000 lawsuits over its Infuse bone growth product.
Pfizer has agreed to change its policy for disclosure of clinical trial data, coming amid an increasing push for trial data transparency.
The Justice Department has released documents suggesting Johnson & Johnson withheld clinical trial data on Risperdal, amid growing concern over drug company's use of clinical trial data that places their…
EMA officials say more clinical trial data transparency would help drug companies become more trustworthy.
